new glp-1 receptor agonists Molecules and Emerging Indications for Medicines Color coding New England Journalist of Medicine

Description

Gastrointestinal side effects are the most frequently reported adverse reactions with GLP-1 receptor agonists, particularly during the initial weeks of treatment or following dose escalation

Abbreviations T2DM: Type 2 Diabetes Mellitus GLP1: Glucagon-like peptide1 GIP: Glucose-dependent insulinotropic polypeptide HbA1c: Hemoglobin A1c GLP1RAs: Glucagon-like peptide1 receptor agonists GIPR: Glucose-dependent insulinotropic polypeptide receptor GLP1R: Glucagon-like peptide1 receptor CVD: Cardiovascular Disease MACE: Major Adverse Cardiovascular Event HF: Heart Failure HFrEF: Heart Failure with Reduced Ejection Fraction HFpEF: Heart Failure with Preserved Ejection Fraction ASCVD: Atherosclerotic Cardiovascular Disease CVOTs: Cardiovascular Outcome Trials SA: Sinoatrial ICAM-1: Intercellular Adhesion Molecule 1 GDF15: Growth Differentiation Factor 15 CRP: C-reactive protein LPS: Lipopolysaccharide TLR4: Toll-like receptor 4 NLRP3: NOD-like receptor protein 3 TNF-: Tumor Necrosis Factor-alpha IL-1: Interleukin-1 beta IL-6: Interleukin-6 TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling BCAA: Branched-chain amino acids BCKA: Branched-chain ketoacids HOMA2-IR: Homeostasis Model Assessment of Insulin Resistance LDL: Low-Density Lipoprotein VLDL: Very Low-Density Lipoprotein BP: Blood Pressure References Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR et al